Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 14/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | MC5R | P33032 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951178 | 0.88 | HCRTR2 (0.55) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL10188723 | 0.88 | HCRTR2 (0.55) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9950652 | 0.85 | HCRTR2 (0.55) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9951705 | 0.83 | HCRTR2 (0.46) | HCRTR2HCRTR1KCNH2SLC6A2SLC6A4 | |
| SCHEMBL9951448 | 0.82 | HCRTR2 (0.42) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9951182 | 0.80 | HCRTR2 (0.58) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL19124706 | 0.79 | HCRTR1 (0.63) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL22666389 | 0.79 | HCRTR1 (0.63) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL2116673 | 0.79 | HCRTR1 (0.63) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL29521573 | 0.79 | HCRTR1 (0.63) | HCRTR2HCRTR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HCRTR2 1/4885HCRTR1 2/4885KCNH2 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.